MedPath

Arterial Thrombosis and Inflammatory Bowel Disease: a Series of 6 Cases and Literature Review

Completed
Conditions
Arterial Thrombosis
Registration Number
NCT02896530
Lead Sponsor
Fondation Hôpital Saint-Joseph
Brief Summary

Vascular complications in patients with inflammatory bowel disease (IBD), comprising mainly Crohn's disease (CD) and ulcerative colitis (UC), representing 2% extra-intestinal complications. In over 60% of cases, these vascular complications of deep venous thrombosis (DVT) or pulmonary embolism (PE). Several studies have shown that patients with IBD have a risk of venous thromboembolic disease (VTE) increased from 1.5 to 3.5. This risk is closely related to disease activity.

Detailed Description

Vascular complications in patients with inflammatory bowel disease (IBD), comprising mainly Crohn's disease (CD) and ulcerative colitis (UC), representing 2% extra-intestinal complications. In over 60% of cases, these vascular complications of deep venous thrombosis (DVT) or pulmonary embolism (PE). Several studies have shown that patients with IBD have a risk of venous thromboembolic disease (VTE) increased from 1.5 to 3.5. This risk is closely related to disease activity.

However, the association between IBD and arterial thromboembolic events such as cases of myocardial infarction, stroke, aortic thrombus, mesenteric ischemia, peripheral arterial disease and members senior, was described less and remains a subject of debate. These arterial complications occur in young subjects accountability of IBD remains debated, and no clear pathophysiology. Here the investigators describe a series of 6 cases of patients with IBD who developed severe arterial complications, and whose cause was retained digestive inflammatory underlying disease.

This study is report of six (6) cases that will be described

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Patients with arterial Thrombosis and Inflammatory Bowel Disease admitted in Paris Saint Joseph Hospital
Exclusion Criteria
  • No exclusion criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of change of the number of thromboembolic events or venous or arterialMonth 6, year 2
Secondary Outcome Measures
NameTimeMethod
Assessment of the relevance of anti thrombosis treatmentMonth 6, year 2

Is the anti thrombosis treatment adequate or have been changed during the monitoring? The answer to this question should be :yes or no

Trial Locations

Locations (1)

Groupe Hospitalier Paris Saint Joseph

🇫🇷

Paris, Ile-de-France, France

© Copyright 2025. All Rights Reserved by MedPath